משפחה

הרצאות מצגות

סיקור וידאו/מולטימדיה מלא של הכנס השנתי 2019 של החברה לטרשת עורקים, כולל גם האקדמיה לטרשת עורקים, מוצג כעת באתר החברה

26/10/2019

לצפייה בהרצאות הכנס באתר החברה - הקליקו כאן

Session 1: Familial Dyslipidemias

Chairpersons: Hofit Cohen Sheba Medical Center, Israel, Euridiki Drogari Kapodistrian University of Athens, Greece

The characteristics of patients with probable Familial Hypercholesterolemia- screening a large payer/provider Healthcare Delivery System

Avishay Elis
Rabin Medical Center, Israel

Session 2: Vascular and Cellular Biology of Atherosclerosis

Chairpersons: Joseph Roitelman Sheba Medical Center, Israel, Kyriakos Kypreos University of Patras, Greece

Inhibition of endothelial progenitor in the first 24 hours of an acute ischemic cerebrovascular event

Arnon Blum
Bar Ilan University, Israel

Exploring glucolipotoxicity in pancreatic beta cells by combining advanced confocal analysis of the subcellular lipid map with proteomics

Shlomo Sasson
The Hebrew University of Jerusalem, Israel

The effect of ambient particulate matter on human adipose tissue

Lior Hassan
Ben-Gurion University of the Negev, Israel

Session 3: Lipid Metabolism, Fatty Liver

Chairpersons: Yehuda Kamari Sheba Medical Center, Israel, Joachim Thiery Universitätsklinikum Leipzig, Germany

The genetics of NAFLD: Focus on PNPLA3

Yehuda Kamari
Sheba Medical Center, Israel

A novel role for GAS3 in hepatic lipid metabolism

Hagai Tavori
Oregon Health & Science University, USA

Metabolic circuit involving free fatty acids, microRNA 122, and triglycerides

Chofit Chai
Sheba Medical Center, Israel

Session 4: A New Era in Lipid-Lowering Therapy

Chairpersons: Ofir Avizohar Rambam Health Care Campus, Israel, Hagai Tavori Oregon Health & Science University, USA

New Opportunities to Reduce Residual Risk Beyond Statin Therapy

Craig Granowitz
Amarin Pharma Inc. NJ, USA

Statin Therapy Among Chronic Kidney Disease Patients Presenting with Acute Coronary Syndrome

Sharon Shalom Natanzon
Sheba Medical Center, Israel

Applying asntisense Technology to treat chylomicronemia and high Lp(a)

Dov Gavish
Wolfson Medical Center , Israel

Further analysis of recent PCSK9i Mega studies: Implications for clinical use

Gabizon Itzhak
Ben-Gurion University of the Negev, Israel

Innovation in CVD &T2D treatments from guidelines to clinical practice

Ronen Durst
Hadassah Hebrew University Medical Center, Israel

Session 5: Diabetes, Obesity and Atherosclerosis

Ilana Harman-Boehm Ben-Gurion University of the Negev, Israel,
Kevin Jon Williams Temple University School of Medicine, USA

A novel pathway essential for canonical insulin and leptin signaling in hypothalamic neurons: a molecular explanation for simultaneous central resistance to the appetite-suppressing effects of two remarkably different hormones in obesity

Kevin Jon Williams, Temple University School of Medicine, USA

The prognostic impact of BMI trajectories after cardiac catheterization on longterm mortality

Elad Shemesh,
Carmel Medical Center, Israel

Specific circulating micro-RNAs are associated with Type 2 Diabetes progression

Maya Sultan,
Meir Medical Center, Israel

Inactivation of the E3 Ubiquitin Ligase IDOL attenuates diet-induced obesity and metabolic dysfunction in mice

Noam Zeicer,
University of Amsterdam, The Netherlands

Session 6: The new ESC dyslipidemia guidelines

Yaakov Henkin Ben-Gurion University, Israel, Ian Graham Trinity College Dublin, Ireland

Update on the new ESC Dyslipidemia Guidelines 2019

Yaakov Henkin,
Ben-Gurion University, Israel

An LDLc target goal of 70-100 mg/dL may be sufficient

Morton Leibowitz
Clalit Health Sevices · Research Instituten

LDLc shoud be lowered to less than 70 mg/dL

Dov Gavish,
Wolfson Medical Center, Israel

Panel discussion – the new guidelines

Moderator: Yaakov Henkin Ben-Gurion University, Israel
Participants: Ian Graham Trinity College Dublin, Ireland; Yosef Rozenman Wolfson Medical Center, Israel; Marielle Kaplan Rambam Health Care Campus, Israel;
Dr Lilach Maletzki Ariel University, Israel